Protein transduction from retroviral Gag precursors

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 17, 2010, Pages 7805-7810

  Voelkel, Christine ^a   Galla, Melanie ^a   Maetzig, Tobias ^a   Warlich, Eva ^a   Kuehle, Johannes ^a   Zychlinski, Daniela ^a   Bode, Juergen ^a   Cantz, Tobias ^a   Schambach, Axel ^a   Baum, Christopher ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Flp recombinase; Murine leukemia virus; Pluripotent cells; Protein transfer

Indexed keywords

ENVELOPE PROTEIN; GAG PROTEIN; GAMMARETROVIRAL PARTICLE; KRUPPEL LIKE FACTOR 4; LENTIVIRUS VECTOR; MYC PROTEIN; NUCLEIC ACID; OCTAMER TRANSCRIPTION FACTOR 4; POLYPROTEIN; PROTEINASE; RECOMBINASE; RETROVIRUS VECTOR; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG;

ARTICLE; CELL CONTACT; EMBEDDING; GENETIC ENGINEERING; GENETIC TRANSDUCTION; GENOME; HUMAN; HUMAN CELL; KINETICS; NUCLEAR LOCALIZATION SIGNAL; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROCESSING; PROTEIN DEGRADATION; PROTEIN TRANSDUCTION; SIGNAL TRANSDUCTION; TRANSGENE;

GENE PRODUCTS, GAG; GENETIC ENGINEERING; GREEN FLUORESCENT PROTEINS; KINETICS; LEUKEMIA VIRUS, MURINE; NUCLEAR LOCALIZATION SIGNALS; PEPTIDE HYDROLASES; TRANSDUCTION, GENETIC; VIRION; VIRUS INTERNALIZATION;

MURINE LEUKEMIA VIRUS;

EID: 77952368672     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0914517107     Document Type: Article

References (53)

1. Gump JM, Dowdy SF (2007) TAT transduction: The molecular mechanism and therapeutic prospects. Trends Mol Med 13:443-448.
2. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF (1999) In vivo protein transduction: Delivery of a biologically active protein into the mouse. Science 285:1569-1572.
3. Morris MC, Depollier J, Mery J, Heitz F, Divita G (2001) A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat Biotechnol 19:1173-1176. (Pubitemid 33115705)
4. Ford KG, Souberbielle BE, Darling D, Farzaneh F (2001) Protein transduction: An alternative to genetic intervention? Gene Ther 8:1-4.
5. Derossi D, Joliot AH, Chassaing G, Prochiantz A (1994) The third helix of the Antennapedia homeodomain translocates through biological membranes. J Biol Chem 269:10444-10450. (Pubitemid 24198241)
6. Dalba C, Bellier B, Kasahara N, Klatzmann D (2007) Replication-competent vectors and empty virus-like particles: New retroviral vector designs for cancer gene therapy or vaccines. Mol Ther 15:457-466. (Pubitemid 46306588)
7. Oshima M, et al. (2004) Effects of blocking individual maturation cleavages in murine leukemia virus gag. J Virol 78:1411-1420. (Pubitemid 38095851)
8. Goff SP (1992) Genetics of retroviral integration. Annu Rev Genet 26:527-544.
9. Bowerman B, Brown PO, Bishop JM, Varmus HE (1989) A nucleoprotein complex mediates the integration of retroviral DNA. Genes Dev 3:469-478.
10. Schambach A, et al. (2006) Equal potency of gammaretroviral and lentiviral SIN vectors for expression of O6-methylguanine-DNA methyltransferase in hematopoietic cells. Mol Ther 13:391-400. (Pubitemid 43056905)
11. Schambach A, et al. (2006) Overcoming promoter competition in packaging cells improves production of self-inactivating retroviral vectors. Gene Ther 13:1524-1533. (Pubitemid 44567149)
12. Fehse B, et al. (2000) CD34 splice variant: An attractive marker for selection of gene-modified cells. Mol Ther 1:448-456.
13. Galla M, Schambach A, Towers GJ, Baum C (2008) Cellular restriction of retrovirus particle-mediated mRNA transfer. J Virol 82:3069-3077. (Pubitemid 351329195)
14. Nightingale SJ, et al. (2006) Transient gene expression by nonintegrating lentiviral vectors. Mol Ther 13:1121-1132. (Pubitemid 43796157)
15. Yáñez-Muñoz RJ, et al. (2006) Effective gene therapy with nonintegrating lentiviral vectors. Nat Med 12:348-353. (Pubitemid 43355085)
16. Lehmann-Che J, et al. (2007) Centrosomal latency of incoming foamy viruses in resting cells. PLoS Pathog 3:e74. (Pubitemid 46827954)
17. Zamborlini A, et al. (2007) Centrosomal pre-integration latency of HIV-1 in quiescent cells. Retrovirology 4:63. (Pubitemid 47570622)
18. Raymond CS, Soriano P (2007) High-efficiency FLP and PhiC31 site-specific recombination in mammalian cells. PLoS One 2:e162.
19. Rulli SJ, Jr., et al. (2007) Selective and nonselective packaging of cellular RNAs in retrovirus particles. J Virol 81:6623-6631.
20. Sandrin V, et al. (2002) Lentiviral vectors pseudotyped with a modified RD114 envelope glycoprotein show increased stability in sera and augmented transduction of primary lymphocytes and CD34+ cells derived from human and nonhuman primates. Blood 100:823-832. (Pubitemid 34832607)
21. Germain E, Roullin VG, Qiao J, de Campos Lima PO, Caruso M (2005) RD114-pseudotyped retroviral vectors kill cancer cells by syncytium formation and enhance the cytotoxic effect of the TK/GCV gene therapy strategy. J Gene Med 7:389-397. (Pubitemid 40553120)
22. Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126:663-676.
23. Qiao J, Oumard A, Wegloehner W, Bode J (2009) Novel tag-and-exchange (RMCE) strategies generate master cell clones with predictable and stable transgene expression properties. J Mol Biol 390:579-594.
24. Oumard A, Qiao J, Jostock T, Li J, Bode J (2006) Recommended method for chromosome exploitation: RMCE-based cassette-exchange systems in animal cell biotechnology. Cytotechnology 50:93-108. (Pubitemid 44243935)
25. Higashi AY, et al. (2009) Direct hematological toxicity and illegitimate chromosomal recombination caused by the systemic activation of CreERT2. J Immunol 182:5633-5640.
26. Anton M, Graham FL (1995) Site-specific recombination mediated by an adenovirus vector expressing the Cre recombinase protein: A molecular switch for control of gene expression. J Virol 69:4600-4606.
27. Soldner F, et al. (2009) Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell 136:964-977.
28. Gilboa E, Vieweg J (2004) Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol Rev 199:251-263.
29. Van Tendeloo VF, Ponsaerts P, Berneman ZN (2007) mRNA-based gene transfer as a tool for gene and cell therapy. Curr Opin Mol Ther 9:423-431. (Pubitemid 47574618)
30. Buchholz CJ, Mühlebach MD, Cichutek K (2009) Lentiviral vectors with measles virus glycoproteins - dream team for gene transfer? Trends Biotechnol 27:259-265.
31. Frecha C, et al. (2008) Stable transduction of quiescent T-cells without induction of cycle progression by a novel lentiviral vector pseudotyped with measles virus glycoproteins. Blood 112:4843-4852.
32. Singh SP, et al. (2000) Epitope-tagging approach to determine the stoichiometry of the structural and nonstructural proteins in the virus particles: Amount of Vpr in relation to Gag in HIV-1. Virology 268:364-371.
33. Link N, et al. (2006) Therapeutic protein transduction of mammalian cells and mice by nucleic acid-free lentiviral nanoparticles. Nucleic Acids Res 34:e16.
34. Schenkwein D, et al. (2009) Production of HIV-1 integrase fusion protein containing lentivirus vectors for gene therapy and protein transduction. Hum Gene Ther, online December 29, 2009, ahead of print, PMID: 20039782.
35. Cavrois M, De Noronha C, Greene WC (2002) A sensitive and specific enzyme-based assay detecting HIV-1 virion fusion in primary T lymphocytes. Nat Biotechnol 20:1151-1154. (Pubitemid 35285446)
36. Auerbach MR, Shu C, Kaplan A, Singh IR (2003) Functional characterization of a portion of the Moloney murine leukemia virus gag gene by genetic footprinting. Proc Natl Acad Sci USA 100:11678-11683.
37. Puglia J, et al. (2006) Revealing domain structure through linker-scanning analysis of the murine leukemia virus (MuLV) RNase H and MuLV and human immunodeficiency virus type 1 integrase proteins. J Virol 80:9497-9510.
38. Sherer NM, et al. (2003) Visualization of retroviral replication in living cells reveals budding into multivesicular bodies. Traffic 4:785-801.
39. Lampe M, et al. (2007) Double-labelled HIV-1 particles for study of virus-cell interaction. Virology 360:92-104. (Pubitemid 46319236)
40. Müller B, et al. (2004) Construction and characterization of a fluorescently labeled infectious human immunodeficiency virus type 1 derivative. J Virol 78:10803-10813. (Pubitemid 39258405)
41. Andrawiss M, Takeuchi Y, Hewlett L, Collins M (2003) Murine leukemia virus particle assembly quantitated by fluorescence microscopy: Role of Gag-Gag interactions and membrane association. J Virol 77:11651-11660. (Pubitemid 37271664)
42. Perrin-Tricaud C, Davoust J, Jones IM (1999) Tagging the human immunodeficiency virus gag protein with green fluorescent protein. Minimal evidence for colocalisation with actin. Virology 255:20-25.
43. Larson DR, Johnson MC, Webb WW, Vogt VM (2005) Visualization of retrovirus budding with correlated light and electron microscopy. Proc Natl Acad Sci USA 102:15453-15458.
44. Hübner W, et al. (2007) Sequence of human immunodeficiency virus type 1 (HIV-1) Gag localization and oligomerization monitored with live confocal imaging of a replication-competent, fluorescently tagged HIV-1. J Virol 81:12596-12607. (Pubitemid 350085873)
45. McDonald D, et al. (2002) Visualization of the intracellular behavior of HIV in living cells. J Cell Biol 159:441-452. (Pubitemid 35332831)
46. Campbell EM, Perez O, Melar M, Hope TJ (2007) Labeling HIV-1 virions with two fluorescent proteins allows identification of virions that have productively entered the target cell. Virology 360:286-293. (Pubitemid 46482608)
47. Verhoeyen E, et al. (2005) Novel lentiviral vectors displaying "early-acting cytokines" selectively promote survival and transduction of NOD/SCID repopulating human hematopoietic stem cells. Blood 106:3386-3395.
48. Baum C, Schambach A, Bohne J, Galla M (2006) Retrovirus vectors: Toward the plentivirus? Mol Ther 13:1050-1063.
49. Vargas J, Jr, Gusella GL, Najfeld V, Klotman ME, Cara A (2004) Novel integrase-defective lentiviral episomal vectors for gene transfer. Hum Gene Ther 15:361-372. (Pubitemid 38469778)
50. Galla M, Will E, Kraunus J, Chen L, Baum C (2004) Retroviral pseudotransduction for targeted cell manipulation. Mol Cell 16:309-315. (Pubitemid 39388845)
51. Miura K, et al. (2009) Variation in the safety of induced pluripotent stem cell lines. Nat Biotechnol 27:743-745.
52. Sommer CA, et al. (2010) Excision of reprogramming transgenes improves the differentiation potential of iPS cells generated with a single excisable vector. Stem Cells 28:64-74.
53. Schambach A, et al. (2006) Lentiviral vectors pseudotyped with murine ecotropic envelope: Increased biosafety and convenience in preclinical research. Exp Hematol 34:588-592.